All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.

2017-06-13T09:17:44.000Z

External monitors press pause on KEYNOTE phase III clinical trials of pembrolizumab

Jun 13, 2017
Share:

Bookmark this article

Much emphasis has been put on immune checkpoint inhibitors as the rising stars in targeted therapy for Multiple Myeloma (MM). Pembrolizumab is one such inhibitor targeting the programmed cell death receptor (PD-1) on lymphocytes, and was a major player in Merck’s portfolio, showing promising results in initial combination trials.

Yesterday an external data monitoring committee put the brakes on two phase III trials, KEYNOTE-183 and KEYNOTE-185, designed to assess the efficacy of pembrolizumab with pomalidomide and low-dose dexamethasone, and lenalidomide and low-dose dexamethasone, respectively. KEYNOTE-183 had enrolled heavily pre-treated MM patients that had received a minimum of two lines of prior treatment and were ineligible for transplant, whereas KEYNOTE-185 had enrolled patients with newly diagnosed MM who were treatment naive.

Patients currently enrolled in the trials will continue as planned, but researchers are no longer allowed to recruit new patients while an investigation is carried out. This decision was taken as a consequence of a higher than expected number of deaths. This will be a big setback for Merck, as a planned expansion of the treatment indication for pembrolizumab into MM would have been resting on these trials. Pembrolizumb is currently approved by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of a number of other cancers, such as melanoma, advanced non-small lung cancer and Hodgkin’s Lymphoma; and by the FDA for the treatment of bladder cancer.

Your opinion matters

HCPs, what is your preferred format for educational content on the Multiple Myeloma Hub?
59 votes - 52 days left ...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox